Onxeo’s new preclinical data confirm the relevance of combining AsiDNA™ with PARP inhibitors in treating homologous recombination proficient tumors
These pioneering data were presented at ESMO Targeted Anticancer Therapies Congress 2022
Paris (France), March 9, 2022 – 7:00 am CET - Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), today announced the presentation of new preclinical data confirming the relevance of combining AsiDNA™ with PARP inhibitors (PARPi) in homologous recombination repair (HRP) tumor models, during poster and oral sessions at the ESMO Targeted Anticancer Therapies Congress (7-8 March, 2022).
Although PARP inhibitors have shown significant benefits in cancer patients with deficient homologous recombination repair (HRD), they show no or very limited efficacy in tumors with active or proficient homologous recombination repair (HRP). The data presented by Onxeo highlight the therapeutic opportunity of combining AsiDNA™ and PARPi in HRP tumors to overcome intrinsic or acquired resistance in clinical situation.
Wael Jdey, Preclinical Lead of Onxeo, stated: “The fact that PARP inhibitors showed limited efficacy in HRP tumors represents a significant unmet need, and addressing these aggressive tumors seems to be challenging. We already showed that AsiDNA disrupts the homologous recombination repair in different HRP tumor models, and therefore, induces a functional HRD that sensitizes HRP tumors to PARP inhibitors. This has been recently validated in preclinical HRP tumor models using more appropriate patient-friendly treatment schedules. Moreover, we also validated the AsiDNA-driven HRD in patient biopsies from DRIIV-1 clinical trial. These new data provide further evidence that our leading drug candidate shows high potential to drive synthetic lethality in combination with PARP inhibitors and reverses the relapse of aggressive tumors during treatment with PARP inhibitors. We are delighted to have had the opportunity to present these new data at the ESMO-TAT Congress and will continue to strengthen our understanding of AsiDNATM’s unique mechanism of action and further explore its capabilities in cancer treatment.”
To read the mini oral presentation: click here.